Human RPTOR/KOG1/Mip1 ORF/cDNA clone-Mammalian (Non-Viral Vector) plasmid (NM_020761.2)
Cat. No.: pGMPC000108
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days
Pre-made Human RPTOR/KOG1/Mip1 Non-Viral expression plasmid (overexpression vector) for mouse RPTOR overexpression in unique cell transient transfection and stable cell line development.
Go to
Raptor/RPTOR/RPTOR/KOG1 products
collection>>
(antibodies,
antigen, VLP, mRNA, ORF viral vector, etc)
Product Description
| Catalog ID | pGMPC000108 |
| Gene Name | RPTOR |
| Accession Number | NM_020761.2 |
| Gene ID | 57521 |
| Species | Human |
| Product Type | Mammalian (Non-Viral Vector) plasmid (overexpression) |
| Insert Length | 4008 bp |
| Gene Alias | KOG1,Mip1 |
| Fluorescent Reporter | ZsGreen |
| Mammalian Cell Selection | Puromyocin |
| Fusion Tag | Null |
| Promoter | CMV |
| Resistance | Amplicin |
| ORF Nucleotide Sequence | ATGGAGTCCGAAATGCTGCAATCGCCTCTTCTGGGCCTGGGGGAGGAAGATGAGGCTGATCTTACAGACTGGAACCTACCTTTGGCTTTTATGAAAAAGAGGCACTGTGAGAAAATTGAAGGCTCCAAATCCTTAGCTCAGAGCTGGAGGATGAAGGATCGGATGAAGACAGTCAGTGTTGCCTTAGTTTTGTGCCTGAATGTTGGTGTGGACCCTCCCGATGTGGTGAAGACCACGCCCTGTGCACGCTTGGAATGCTGGATCGATCCTCTGTCGATGGGTCCTCAGAAAGCTCTGGAAACCATCGGTGCAAATTTACAGAAGCAGTACGAGAACTGGCAGCCAAGGGCCCGGTACAAGCAGAGCCTTGACCCAACTGTGGATGAAGTCAAGAAGCTCTGCACGTCCTTACGTCGCAACGCCAAGGAGGAGCGAGTCCTCTTTCACTACAATGGCCACGGGGTGCCCCGGCCCACAGTCAACGGGGAGGTCTGGGTCTTCAACAAGAACTACACGCAGTACATCCCTCTGTCCATATATGACCTGCAGACGTGGATGGGCAGCCCGTCGATCTTCGTCTACGACTGCTCCAATGCTGGCTTGATCGTCAAGTCCTTCAAGCAGTTCGCACTACAGCGGGAGCAGGAGCTGGAGGTAGCTGCAATCAACCCAAATCACCCTCTTGCTCAGATGCCTTTGCCTCCGTCGATGAAAAACTGCATCCAGCTGGCAGCCTGCGAGGCCACCGAGCTGCTGCCCATGATCCCCGACCTCCCGGCTGACCTATTCACCTCCTGCCTCACCACCCCCATCAAGATCGCCCTGCGCTGGTTTTGCATGCAGAAATGTGTCAGTCTGGTGCCTGGCGTCACACTGGATTTGATAGAAAAGATCCCTGGCCGCCTGAACGACAGGAGGACGCCCCTGGGTGAACTGAACTGGATCTTCACAGCCATCACAGACACCATCGCGTGGAACGTGCTCCCCCGGGATCTCTTCCAAAAGCTCTTCAGACAGGACTTGCTGGTGGCTAGTCTGTTTCGAAATTTTTTATTGGCGGAAAGGATTATGAGGTCGTATAACTGCACTCCCGTCAGCAGCCCGCGTCTGCCGCCCACGTACATGCACGCCATGTGGCAAGCCTGGGACCTGGCTGTTGACATCTGTCTGTCTCAGCTGCCGACGATCATCGAGGAAGGCACTGCGTTTCGGCACAGCCCGTTCTTCGCCGAGCAGCTGACCGCATTCCAGGTGTGGCTCACCATGGGCGTGGAGAACCGAAACCCACCCGAACAGCTGCCCATCGTCCTGCAGGTGCTGTTAAGCCAAGTGCACCGGCTGAGAGCATTGGACTTGCTTGGAAGATTTTTGGACCTGGGTCCCTGGGCAGTGAGCCTGGCCTTGTCTGTCGGCATCTTCCCCTACGTGCTGAAGCTGCTCCAGAGCTCGGCCCGAGAGCTGCGGCCACTTCTCGTTTTCATCTGGGCCAAGATCCTCGCAGTGGACAGCTCGTGCCAAGCGGACCTCGTGAAGGACAACGGCCACAAGTACTTCCTGTCGGTCCTGGCGGACCCCTACATGCCAGCTGAACACCGGACCATGACGGCTTTCATTCTCGCCGTGATCGTCAACAGCTATCACACGGGGCAGGAAGCCTGCCTTCAGGGAAACCTCATTGCCATCTGCCTGGAGCAGCTCAACGACCCGCACCCCTTGCTGCGCCAGTGGGTGGCCATCTGCCTCGGCAGGATCTGGCAGAACTTCGACTCGGCGAGGTGGTGCGGCGTGAGGGACAGCGCTCATGAGAAGCTCTACAGCCTCCTCTCCGACCCCATTCCCGAGGTCCGCTGCGCAGCGGTCTTCGCCCTTGGCACGTTCGTGGGCAACTCTGCAGAGAGGACGGACCACTCCACCACCATCGACCACAACGTGGCCATGATGCTGGCCCAGCTGGTCAGCGACGGGAGCCCCATGGTCCGGAAGGAGCTGGTGGTGGCTCTGAGTCATCTTGTGGTTCAGTATGAAAGCAATTTCTGCACCGTGGCCCTGCAGTTCATAGAAGAGGAAAAGAACTACGCCTTGCCTTCTCCAGCAACCACAGAGGGAGGGAGTTTGACCCCAGTGCGAGACAGCCCGTGCACCCCCAGACTTCGTTCTGTGAGCTCCTATGGAAACATCCGTGCTGTCGCCACAGCCAGGAGCCTCAACAAATCTTTGCAGAACCTGAGTTTGACAGAGGAATCTGGTGGCGCGGTGGCGTTCTCCCCCGGAAACCTCAGCACCAGCAGCAGCGCCAGCAGCACCCTGGGCAGCCCCGAGAATGAGGAGCATATCCTGTCCTTCGAGACCATCGACAAGATGCGCCGCGCCAGCTCCTACTCCTCCCTCAACTCCCTCATCGGAGTTTCCTTTAACAGTGTTTACACTCAGATTTGGAGAGTCCTGCTGCACCTGGCTGCTGACCCCTATCCAGAGGTCTCGGACGTGGCCATGAAAGTACTCAACAGCATCGCCTACAAGGCCACCGTGAACGCCCGGCCGCAGCGCGTCCTGGACACCTCCTCCCTCACGCAGTCGGCCCCCGCCAGCCCCACCAACAAGGGCGTGCACATCCACCAGGCGGGGGGCTCCCCTCCGGCGTCCAGCACCAGCAGCTCCAGCCTGACCAACGATGTGGCCAAGCAGCCGGTCAGCCGAGACTTGCCTTCTGGCCGGCCGGGCACCACAGGCCCCGCTGGGGCGCAGTACACCCCTCACTCCCACCAGTTCCCCCGGACACGGAAGATGTTCGACAAGGGCCCAGAGCAGACTGCGGACGACGCGGACGATGCTGCTGGACACAAAAGTTTCATCTCCGCCACGGTGCAGACGGGGTTCTGCGACTGGAGCGCCCGCTATTTTGCCCAGCCCGTCATGAAGATCCCAGAAGAGCACGACCTGGAGAGTCAGATCCGCAAGGAGCGGGAGTGGCGGTTCCTGCGAAACAGCCGTGTCAGGAGGCAGGCCCAGCAAGTCATTCAGAAGGGCATTACGAGATTGGACGACCAAATATTTCTGAACAGGAACCCCGGCGTCCCCTCTGTGGTGAAATTCCACCCCTTCACGCCGTGCATCGCCGTAGCCGACAAGGACAGCATCTGCTTTTGGGACTGGGAGAAAGGGGAGAAGCTGGATTATTTCCACAATGGGAACCCTCGGTACACGAGGGTCACTGCCATGGAGTATCTGAACGGCCAGGACTGCTCGCTTCTGCTGACGGCCACAGACGATGGTGCCATCAGGGTCTGGAAGAATTTTGCTGATTTGGAAAAGAACCCAGAGATGGTGACCGCGTGGCAGGGGCTCTCGGACATGCTGCCAACGACGCGAGGAGCTGGGATGGTGGTGGACTGGGAGCAGGAGACCGGCCTCCTCATGAGCTCAGGAGACGTGCGGATCGTCCGGATCTGGGACACAGACCGTGAGATGAAGGTGCAGGACATCCCTACGGGCGCAGACAGCTGTGTGACGAGTCTGTCCTGTGATTCCCACCGCTCACTCATCGTGGCTGGCCTCGGTGACGGCTCCATCCGCGTCTACGACAGAAGGATGGCACTCAGCGAATGCCGCGTCATGACGTACCGGGAGCACACAGCCTGGGTGGTGAAGGCCTCCCTGCAGAAGCGTCCCGACGGCCACATCGTGAGTGTGAGCGTCAATGGAGATGTGCGCATCTTTGATCCCCGGATGCCTGAGTCGGTAAATGTGCTTCAGATCGTGAAGGGGCTGACGGCCCTGGACATCCACCCCCAGGCGGACCTGATCGCATGTGGCTCCGTCAATCAGTTCACCGCCATCTACAACAGCAGCGGAGAGCTCATCAACAACATCAAGTACTACGACGGCTTCATGGGCCAGCGGGTCGGCGCCATCAGCTGCCTGGCCTTCCACCCGCACTGGCCTCACCTGGCCGTGGGAAGCAACGACTACTACATCTCCGTGTACTCGGTGGAGAAGCGTGTCAGATAG |
| ORF Protein Sequence | MESEMLQSPLLGLGEEDEADLTDWNLPLAFMKKRHCEKIEGSKSLAQSWRMKDRMKTVSVALVLCLNVGVDPPDVVKTTPCARLECWIDPLSMGPQKALETIGANLQKQYENWQPRARYKQSLDPTVDEVKKLCTSLRRNAKEERVLFHYNGHGVPRPTVNGEVWVFNKNYTQYIPLSIYDLQTWMGSPSIFVYDCSNAGLIVKSFKQFALQREQELEVAAINPNHPLAQMPLPPSMKNCIQLAACEATELLPMIPDLPADLFTSCLTTPIKIALRWFCMQKCVSLVPGVTLDLIEKIPGRLNDRRTPLGELNWIFTAITDTIAWNVLPRDLFQKLFRQDLLVASLFRNFLLAERIMRSYNCTPVSSPRLPPTYMHAMWQAWDLAVDICLSQLPTIIEEGTAFRHSPFFAEQLTAFQVWLTMGVENRNPPEQLPIVLQVLLSQVHRLRALDLLGRFLDLGPWAVSLALSVGIFPYVLKLLQSSARELRPLLVFIWAKILAVDSSCQADLVKDNGHKYFLSVLADPYMPAEHRTMTAFILAVIVNSYHTGQEACLQGNLIAICLEQLNDPHPLLRQWVAICLGRIWQNFDSARWCGVRDSAHEKLYSLLSDPIPEVRCAAVFALGTFVGNSAERTDHSTTIDHNVAMMLAQLVSDGSPMVRKELVVALSHLVVQYESNFCTVALQFIEEEKNYALPSPATTEGGSLTPVRDSPCTPRLRSVSSYGNIRAVATARSLNKSLQNLSLTEESGGAVAFSPGNLSTSSSASSTLGSPENEEHILSFETIDKMRRASSYSSLNSLIGVSFNSVYTQIWRVLLHLAADPYPEVSDVAMKVLNSIAYKATVNARPQRVLDTSSLTQSAPASPTNKGVHIHQAGGSPPASSTSSSSLTNDVAKQPVSRDLPSGRPGTTGPAGAQYTPHSHQFPRTRKMFDKGPEQTADDADDAAGHKSFISATVQTGFCDWSARYFAQPVMKIPEEHDLESQIRKEREWRFLRNSRVRRQAQQVIQKGITRLDDQIFLNRNPGVPSVVKFHPFTPCIAVADKDSICFWDWEKGEKLDYFHNGNPRYTRVTAMEYLNGQDCSLLLTATDDGAIRVWKNFADLEKNPEMVTAWQGLSDMLPTTRGAGMVVDWEQETGLLMSSGDVRIVRIWDTDREMKVQDIPTGADSCVTSLSCDSHRSLIVAGLGDGSIRVYDRRMALSECRVMTYREHTAWVVKASLQKRPDGHIVSVSVNGDVRIFDPRMPESVNVLQIVKGLTALDIHPQADLIACGSVNQFTAIYNSSGELINNIKYYDGFMGQRVGAISCLAFHPHWPHLAVGSNDYYISVYSVEKRVR |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
|---|---|---|
| Target Antibody | GM-Tg-g-IP1556-Ab | Anti-RPTOR monoclonal antibody |
| Target Antigen | GM-Tg-g-IP1556-Ag | RPTOR protein |
| ORF Viral Vector | pGMLP005708 | Human RPTOR Lentivirus plasmid |
| ORF Viral Vector | pGMPC000108 | Human RPTOR Mammalian (Non-Viral Vector) plasmid |
| ORF Viral Vector | vGMLP005708 | Human RPTOR Lentivirus particle |
Target information
| Target ID | GM-IP1556 |
| Target Name | Raptor/RPTOR |
|
Gene Group Identifier (Target Gene ID in Homo species) |
57521 |
| Gene ID |
100056244 (Equus caballus), 101086862 (Felis catus), 287871 (Rattus norvegicus), 507056 (Bos taurus) 57521 (Homo sapiens), 608378 (Canis lupus familiaris), 712848 (Macaca mulatta), 74370 (Mus musculus) |
| Gene Symbols & Synonyms | RPTOR,Rptor,RGD1311784,KOG1,Mip1,Rap,Raptor,mKIAA1303,4932417H02Rik |
| Target Alternative Names | 4932417H02Rik,KOG1,Mip1,RGD1311784,RPTOR,Rap,Raptor,Regulatory-associated protein of mTOR,Rptor,mKIAA1303,p150 target of rapamycin (TOR)-scaffold protein |
| Uniprot Accession |
Q8K4Q0,Q8N122
Additional SwissProt Accessions: Q8N122,Q8K4Q0 |
| Uniprot Entry Name | |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | |
| Disease from KEGG | PI3K-Akt signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species |
| Gene Ensembl | ENSECAG00000017757, ENSBTAG00000002883, ENSG00000141564, ENSCAFG00845012286, ENSMMUG00000006761, ENSMUSG00000025583 |
| Target Classification |
About GMVC

GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.


